Alamar Biosciences, Inc. ALMR
—
32.80
(0.40)
(1.20%)
as of 25 Sep
- Market cap
- $2.4B
- P/E
- 0.0×
Follow ALMR
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | — | 0.00 |
+2 more quarters Free account |
P/S ratio |
18.76 | 0.00 | — | 0.00 | |
P/FCF ratio |
0.00 | 0.00 | — | 0.00 | |
P/Operating CF |
(140.37) | (13.26) | — | (13.26) | |
P/B ratio |
5.08 | 0.00 | — | 0.00 | |
Price to Tangible BV |
5.11 | 0.00 | — | 0.00 | |
EV/Sales |
15.93 | 0.00 | — | 0.00 | |
EV/EBITDA |
0.00 | 0.00 | — | 0.00 | |
EV/Operating CF |
(13.89) | (2.83) | — | (2.83) | |
EV/FCF |
(12.55) | (2.64) | — | (2.64) | |
Quick Ratio |
9.67 | 3.50 | 1.80 | — | |
Current Ratio |
11.85 | 5.88 | 3.99 | — | |
Net Debt/EBITDA |
19.26 | (0.93) | 0.00 | 0.00 | |
Debt/Assets |
2.54% | 40.21% | 7.01% | 0.00% | |
Debt/Equity |
0.03 | 1.32 | 0.13 | 0.00 | |
Asset Turnover |
0.43 | 0.00 | — | — | |
Operating CF/Net income |
0.86 | 0.95 | 0.00 | 1.69 | |
Capex/Depreciation |
(3.41) | (0.49) | (1.37) | (0.79) | |
Interest Coverage |
0.00 | 0.00 | — | 0.00 | |
Research and Development Expense of Revenue |
46.95% | 50.00% | — | 55.04% | |
Selling, General and Administrative Expense of Revenue |
59.24% | 52.96% | — | 47.05% | |
Intangible Assets out of Total Assets |
0.00 | 0.01 | 0.01 | 0.00 | |
Share Based Compensation of Revenue |
11.15% | 5.63% | — | 4.21% | |
Graham Net Nets |
0.16 | 0.04 | — | 0.04 | |
Graham Number |
0.00 | 0.00 | — | 0.00 | |
Earnings Yield |
(12.02%) | (12.02%) | — | (12.02%) | |
Free Cash Flow Yield |
(6.77%) | (39.37%) | — | (39.37%) | |
Revenue per Share |
0.50 | 2.12 | — | 1.42 | |
Operating CF per Share |
(0.19) | (1.66) | 0.00 | (1.04) | |
Capex per Share |
(0.06) | (0.05) | 0.00 | (0.07) | |
Free Cash Flow per Share |
(0.26) | (1.71) | 0.00 | (1.11) | |
Cash per Share |
4.26 | 5.27 | 0.00 | 0.00 | |
Shareholders Equity per Share |
5.33 | 4.64 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.33 | 4.64 | 0.00 | 0.00 | |
Free Cash Flow |
(14.96) | (20.95) | (58.98) | (12.63) | |
Working Capital |
303.42 | 117.43 | 70.98 | — | |
Capital Expenditures |
(3.64) | (0.60) | (5.37) | (0.75) | |
Net Current Asset Value |
253.26 | 11.95 | 30.76 | 0.00 | |
EV/EBIT |
0.00 | 0.00 | — | 0.00 | |
Capex to Sales |
0.12 | 0.02 | 0.00 | 0.05 | |
Net Profit Margin |
(44.85%) | (81.91%) | — | (43.45%) | |
Price to Operating Income |
0.00 | 0.00 | — | 0.00 | |
| Other line items | |||||
Average Assets |
195.49 | 167.98 | — | — |
Columns are period end dates